A detailed history of Rhumbline Advisers transactions in Argenx Se stock. As of the latest transaction made, Rhumbline Advisers holds 3,542 shares of ARGX stock, worth $2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,542
Previous 1,284 175.86%
Holding current value
$2 Million
Previous $552,000 247.83%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$434.22 - $551.9 $980,468 - $1.25 Million
2,258 Added 175.86%
3,542 $1.92 Million
Q2 2024

Aug 01, 2024

SELL
$356.01 - $451.55 $338,921 - $429,875
-952 Reduced 42.58%
1,284 $552,000
Q1 2024

May 09, 2024

BUY
$356.95 - $413.29 $63,180 - $73,152
177 Added 8.6%
2,236 $880,000
Q4 2023

Feb 08, 2024

SELL
$338.91 - $506.01 $677 - $1,012
-2 Reduced 0.1%
2,059 $783,000
Q3 2023

Nov 09, 2023

SELL
$369.35 - $548.43 $120,777 - $179,336
-327 Reduced 13.69%
2,061 $1.01 Million
Q2 2023

Aug 08, 2023

BUY
$360.14 - $422.58 $860,014 - $1.01 Million
2,388 New
2,388 $930,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.